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ABSTRACT
This study was undertaken to determine the role of human parvovirus B19 (B19) in 
chronic anaemia of HIV infected TB patients. Patients were selected from an existing 
databank of 307 patients included in a MRC HIV/TB study. Twenty-nine patients, 15 
coinfected with HIV/TB and 14 infected with TB only, were identified for further 
evaluation. These patients’ sera were subjected to serological and DNA detection studies 
using IgG and IgM ELISA methods and a nested polymerase chain reaction (PCR) 
assay. The selection of the nested PCR was based on comparative evaluation of a new 
rapid 99 cycle PCR method recommended for hepatitis B DNA detection and the nested 
PCR method established for B19. The nested assay was shown to be the more sensitive 
system in the context of B19 DNA detection. Serological evaluation of these 29 patients 
suggested that a greater proportion of HIV/TB patients with chronic anaemia had 
evidence of recent or past exposure to B19 than those not experiencing anaemia. The 
nested PCR demonstrated the presence of circulating B19 DNA in 2 coinfected 
individuals with haematological pictures compatible with persistent B19 infection. B19 
DNA was also demonstrated in a TB only patient without anaemia; further 
haematological and serological evidence in this patient suggested recent exposure to B19. 
The serological and DNA amplification assay results of these 29 patients would suggest 
a possible role - either causal or co-factorial - for persistent B19 infection in the 
establishment of chronic anaemia in HIV/TB patients.
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1 INTRODUCTION
1.1 History
Human Parvovirus B19 (B19) was first described in 1975 (Cossart et al, 1975) when 
electronmicroscopic investigation of sera yielding discrepant hepatitis B surface antigen 
results, demonstrated virus-like particles with a diameter of approximately 23nm. Further 
morphological evaluation and buoyant density studies strongly suggested that these particles 
were parvoviruses. For the next couple of years it was generally assumed that B19 infection 
was common, and mostly asymptomatic. However, since 1981 when B19 was identified as 
the cause of aplastic crises in children with sickle cell anaemia (Pattison et al, 1981), B19 
has been associated with a variety of other clinical syndromes. The clinical syndromes 
shown to be most commonly associated with B19 infection include the following: erythema 
infectiosum (Anderson et al, 1983; Anderson et al, 1985(a); Plummer et al, 1985), poly­
arthralgia (Reid et al, 1985), intrauterine infection (Mortimer et al, 1985; Gray et al, 1986; 
Bond et al, 1986; Lefrere et al, 1986) and anaemia in immunocompromised individuals 
(Kurtzman et al, 1987; Kurtzman et al, 1988).
1.2 Classification
B19 is a member of the family Parvoviridae. The name "Parvo" was derived from the Latin 
word "Parvus" meaning small.
Characteristics of the Parvoviridae family are the following:
a) single-stranded DNA, 5,5kb, mostly negative sense;
b) non-enveloped icosahedral particles, 18-22 nm in diameter;
c) a buoyant density of 1.39-1.42 g/cm3 in CsCl, stable in lipid solvents and pH 3-9;
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d) most members of the parvoviridae family replicate independently in the nucleus of 
infected cells. Helper virus coinfection, with either herpesviruses or adenoviruses, 
is however required for efficient replication by members of the genus Dependovirus 
(Francki et al (eds.), 1991).
The Parvoviridae family is divided into the following 3 genera (see Fig. 1):
(a) The Dependoviruses. e.g. adeno-associated virus (AAV) type 1. Characteristically 
the members of this genus are dependent on coinfection with herpesviruses or 
adenoviruses for effective replication, although limited independent replication has 
been demonstrated under very specific conditions. Infection by members of this 
genus has been demonstrated in cattle, chickens, dogs, horses, monkeys, sheep and 
man, although AAV infection has not been established as a causal link of disease in 
man (Francki et al (eds.), 1991).
(b) The Densoviruses. e.g. galleria densovirus. Members of this genus are not dependent 
on coinfection by helper viruses for effective replication. Replication is marked by 
the aggregation of dense, intranuclear inclusions and hypertrophic nuclei in infected 
cells. Densoviruses infect insects of the orders Diptera, Lepidoptera and Arthoptera 
and have also been demonstrated in crustaceans such as crabs and shrimps (Francki 
et al (eds.), 1991).
(c) The Parvoviruses, e.g. human parvovirus B19. This group of viruses is not reliant 
on coinfection with helper viruses but effective replication is usually restricted to 
actively proliferating cells which provide essential helper functions. Vertical 
transmission of members of this genus by means of placenta (man) and ova (goose) 
has been demonstrated. The host range of this genus is restricted to vertebrates and
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infection has been demonstrated in cats, cattle, chickens, dogs, geese, man, rats, 
mice, mink, raccoons, rabbits and pigs. (Francki et al (eds.), 1991).
Fig. 1 Classification of Parvoviridae.
Family: Parvoviridae
fimu&i D ependoviruses Densoviruses Parvoviruses
Galleria densovirus Human parvovirus B19
M embers: Adeno-associated virus (AAV) type 1
(AAV) type 2 Junoria densovirus Aleutian mink disease parvovirus
(AAV) type 3 Agraulis densovirus Bovine parvovirus
(AAV) type 4 Bombyx densovirus Feline parvovirus
(AAV) type 5 Goose parvovirus
Avia AAV H I
Bovine AAV Lapine parvovirus
Canine AAV L u I H
Porcine parvovirus
Rat virus
RT
TVX
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1.3 Morphology and antigenic structure
B19 virions are non-enveloped and display the following characteristics:
a) icosahedral symmetry (Fig. 2);
b) range in diameter from 20-25 nm with a mean of 23 nm (Cossart et al, 1975);
c) the buoyant density ranges from 1.41-1.45, mean of 1.43, in CsCl (Clewley et 
al, 1984);
d) the capsid consists of two definite capsid proteins:
i) VP1 with an approximate molecular weight of 83 kilodaltons (kd);
ii) VP2 with an approximate molecular weight of 60 kd;
VP2 is the predominant protein and accounts for approximately 80% of the total protein mass 
(Cotmore et al, 1986). Isolated reports have described the existence of a third capsid protein 
of 48 kd (Clewley et al, 1984).
e) stable and resistant to ether and chloroform. Infectivity is compromised by acid (0,5 
N HC1), alkali (0,05 N Na OH) and heating at 56°C for 5 minutes (Anderson, 1991).
Fig. 2 Electron micrograph of B19 virus particles.
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1.4 Genome organization
The B19 genome is single-stranded DNA and 5,5 kb in length with hairpin structures at the 
5' and 3' ends (Francki et al (eds.), 1991). The mature virions of most members of the 
genus contain minus-strand DNA (Francki et al (eds), 1991), but B19 encapsidates both plus 
and minus strands into separate virions with almost similar efficiency (Clewley et al, 1984). 
The B19 genome has 2 open reading frames (ORFs), situated at the 3' end and 5' end, 
coding for the nonstructural and structural proteins respectively (Cotmore et al, 1986) 
(Fig. 3). Five B19 genotypes have been found when using restriction endonuclease analysis 
but no antigenic differences have been described and a single stable antigenic type is thought 
to exist (Sargeant et al, 1981; Paver et al, 1976).
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Fig. 3 Genome organization of B19.
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The pathogenesis of B19 associated disease can be divided into two components:
a) a cytolytic infection in rapidly dividing susceptible cells and
b) an immunological response to viral products.
1.5.1 Cytolytic infection
A productive B19 infection is dependent on helper functions being supplied by infected cells 
and needs to infect rapidly dividing cells. B19 infects erythroid precursor cells in bone 
marrow, interrupts erythrocyte production (Mortimer et al, 1983; Potter et al, 1987) and is 
responsible for cytolysis. This transient erythrocyte precursor infection is usually of little 
or no clinical significance in haematologically competent individuals (Potter et al, 1987) but 
may, in patients with a shortened red blood cell survival time, lead to aplastic crises (Pattison 
et al, 1981). B19 infection can persist in the foetus due to the immaturity of the foetal 
immune response, resulting in cessation of erythrocyte production and eventually leading to 
the development of hydrops foetalis (Bond et al, 1986; Anderson et al, 1988). Persistence 
of B19 infection with a resultant chronic anaemia is also demonstrated in 
immunocompromised individuals, including AIDS patients (Kurtzman et al, 1987; Kurtzman 
et al, 1988; Frickhofen et al, 1990).
1.5.2 Immunological response
An immunological response to viral products in the form of anti-IgM and IgG antibodies is 
usually seen 12 to 18 days after exposure and coincides with the appearance of a 
maculo-papular rash in infected individuals (Anderson et al, 1985(a); Plummer et al, 1985) 
(Fig.4). In immunocompromised individuals with chronic B19 infection, the administration
1.5 Pathogenesis
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of immunoglobulin containing anti-B19 antibodies can also lead to the appearance of signs 
and symptoms of erythema infectiosum or fifth disease (Kurtzman et al, 1988), further 
suggesting that the humoral immune response is partially responsible for the clinical signs 
following B19 infection.
1.6 Epidemiology
Widespread B19 seroprevalence studies had been limited until recently due to difficulties in 
obtaining B19 antigen from viraemic individuals for use in serological assays. A limited 
number of serological studies performed worldwide, reported adult seroprevalence rates of 
30-60% in the developed world (MMWR, 1989). Reports from the developing world found 
adult seroprevalence rates of 25% (Schoub et al, 1993) and 46% (De Freitas et al, 1990) 
respectively. Recent reports also suggested an increased B19 seroprevalence rate in HIV 
infected individuals. (Frickhofen et al, 1990; Nigro et al, 1992; Arakelov et al, 1993).
B19 infection usually occurs during late winter, spring and early summer in temperate 
climates, leading to outbreaks in primary schools; infection can also subsequently spread to 
susceptible adult contacts of infected children. This pattern of infection was demonstrated 
in observations regarding the epidemiology of erythema infectiosum and in limited serological 
studies where the acquisition of anti-B19 antibody occurred mostly between the ages of 4 and 
10 years and although antibodies against B19 are still acquired after this age, it takes place 
at a much slower rate (Anderson, 1991).
Transmission of B19 occurs mainly via the respiratory route (Anderson et al, 1985(a)) as a 
result of viral presence in the throat for approximately 5 days. The appearance of virus in 
the throat, usually a week after exposure, coincides with the intense viraemia of 10" particles 
per millilitre blood seen during the incubation period of B19 infection (Fig. 4).
7
Transplacental and parenteral transmission of B19 infection are also associated with this 
viraemic stage (Mortimer et al, 1983(a); Bond et al, 1986).
0 4 8 12 16 20 24 28
Days
clinical
illness
non-specific
symptoms
rash and 
arthralgia
Fig. 4 Schematic presentation illustrating the clinical, virological and immunological 
characteristics following on B19 infection.
1.7 Clinical associations
B19 infection, as is the case in other common viral childhood infections, ranges from being 
clinically asymptomatic (Chorba et al, 1986) to causing a life threatening anaemia in a small 
number of predisposed individuals (Pattison et al, 1981).
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Since its description in 1974, a number of clinical syndromes have been associated with B19 
infection and include the following:
a) erythema infectiosum/fifth disease;
b) aplastic crises in predisposed individuals;
c) complications during pregnancy;
d) B19-associated arthropathy;
e) anaemia in immunocompromised individuals.
1.7.1 Erythema infectiosum (E.I.)/Fifth disease
B19 infection was associated with an outbreak of erythema infectiosum or fifth disease in 
London in 1983 (Anderson et al, 1984) and a causal role for B19 in El has since been 
described (Anderson et al, 1985(a)).
Classical El is seen in children aged 4-10 years and presents as a marked erythema of the 
cheeks - the so-called "slapped-cheek" appearance. This usually follows 5-7 days after a 
prodromal illness of malaise, pyrexia and upper respiratory symptoms which is associated 
with an intense viraemia (Fig. 4). The erythematous maculopapular rash subsequently 
spreads to cover large areas on the trunk and limbs, usually lasting 2-3 days but may 
recrudesce up to three weeks after the initial episode upon exposure to sunlight, exercising 
or bathing (Plummer et al, 1985; Anderson, 1991). In older individuals B19 infection is less 
frequently associated with erythema infectiosum but manifests more commonly with an 
arthropathy (Woolf et al, 1989).
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1.7.2 Aplastic crises in predisposed individuals
B19 infection of erythrocyte precursors is of little or no clinical significance in 
haematologically competent individuals (Potter et al, 1987), but poses a significant threat to 
patients with a shortened red blood cell survival time and may precipitate aplastic crisis in 
these patients (Pattison et al, 1981; Sargeant et al, 1981).
In 1981 infection with B19 was demonstrated to cause aplastic crisis in children with sickle 
cell anaemia (Pattison et al, 1981) and these findings were also confirmed in Jamaica on 
sickle cell anaemia patients (Sargeant et al, 1981). Subsequent reports demonstrated that B19 
infection may be responsible for aplastic crisis in patients suffering from a variety of chronic 
haemolytic anaemias such as pyruvate kinase deficiency (Duncan et al, 1983), hereditary 
spherocytosis (Green et al, 1984), dyserythropoietic anaemia (West et al, 1986) and 
autoimmune haemolytic anaemia (Bertrand et al, 1985).
1.7.3 Complications during pregnancy
B19 infected individuals demonstrate a high-titre viraemia 7 days after exposure (Anderson 
et al, 1985(a)) and this may, in pregnant females, result in virus crossing the placenta and 
infecting the foetus. Infection by B19 during the first trimester can result in spontaneous 
abortion and foetal loss (Mortimer et al, 1985; Gray et al, 1986). Hydrops foetalis is 
associated with maternal B19 infection during the second trimester of pregnancy. The 
development of hydrops foetalis may follow up to 12 weeks after maternal infection and is 
the result of B19 persistence in the erythrocyte precursors due to the failure of the immature 
foetal immune response to clear the infection (Bond et al, 1986; Anderson et al, 1988). 
Third trimester infections by B19, although not extensively documented, are also thought to
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be associated with hydrops foetalis (Porter et al, 1988). Teratogenicity has not been 
associated with B19 infection (Cramp et al, 1977; PHLS, 1993).
1.7.4 B19-associated arthropathy
B19-associated arthropathy is the most common complication in immunocompetent and 
haematological normal individuals, with approximately 8% of children and up to 80% of 
adults reporting arthralgia (Ager et al, 1966; Anderson et al, 1984).
These observations were confirmed by serological evidence of B19 infection in patients 
suffering from arthritis after an outbreak of erythema infectiosum (Reid et al, 1985), this 
investigation also confirmed the preponderance of females to suffer from B19 associated 
arthropathy. Arthritis following B19 infection is usually symmetrical, affecting the wrist, 
small joints of the hands, knees and ankles, and mostly resolves within 2-4 weeks (Reid et 
al, 1985; White et al, 1985). In extreme cases, B19 associated arthropathy may continue for 
months and even years (White et al, 1985).
1.7.5 Anaemia in immunocompromised patients
In immunocompetent individuals the development of neutralizing antibodies, approximately 
12-18 days after infection, is associated with the clearance of B19 from the circulation 
(Anderson et al, 1985(a)).
Immunocompromised individuals infected with B19 may not mount an adequate immune 
response, subsequent viral persistence follows which could lead to chronic anaemia. B19 
persistence is well described in patients with Nezelof s syndrome (Kurtzman et al, 1987), 
combined immunodeficiency (Kurtzman et al, 1989) and leukaemia (Kurtzman et al, 1988; 
Coulombel et al, 1989; Davidson et al, 1989); the clinical picture has been that of a chronic
11
or relapsing anaemia coinciding with B19 viraemia, usually in the presence of a weak 
humoral response (Kurtzman et al, 1988). Immunoglobulin has been used in the treatment 
of these chronic B19 infections but with limited success (Kurtzman et al, 1988; Kurtzman 
et al, 1989).
1.7.6 Anaemia in HIV disease
HIV infection, as well as late-stage HIV disease, have been associated with granulocytopenia, 
thrombocytopenia and anaemia. Of these three, anaemia is most commonly associated with 
HIV infection and HIV disease and was shown to be present in 10-23% of recently infected 
HIV infected patients and in approximately 70-80% of patients during late stage disease. 
Reduced haematopoiesis as a result of anti-HIV chemotherapy, neoplastic disease and various 
infections were shown to be largely responsible for anaemia during HIV infection (Doweiko, 
1993).
HIV infection inhibits haematopoiesis by means of infection of various haematopoietic 
progenitor cells and by infection of bone-marrow stromal cells. Opportunistic infections due 
to HIV mediated immunosuppression also plays a major role in causing anaemia in these 
patients. Opportunistic B19 infection in other immunocompromised patients has been shown 
to be associated with chronic anaemia. A recent report has demonstrated the presence of B19 
in the bone marrow of HIV infected patients with anaemia (Frickhofen et al, 1990). 
Subsequent reports have also demonstrated an increase in B19 seroprevalence in HIV infected 
individuals (Nigro et al, 1990; Arakelov et al, 1993) providing evidence that opportunistic 
B19 infection may be an important cause of chronic anaemia in HIV infected individuals.
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1.8 Diagnostic issues
B19 infection can be diagnosed by means of the following laboratory techniques:
a) Viral culture
b) Viral detection
c) Serology
c) DNA hybridization
e) DNA amplification
1.8.1 Viral culture
Routine in vitro viral culture is not undertaken as conventional cell lines do not support the 
growth of B19. The absence of suitable cell lines for the propagation of B19 infection has 
been a limiting factor in the diagnosis of B19 infection and has also, until recently, hampered 
the development of serological assays for the detection of B19 antibodies.
B19 has been cultured in the research setting using specialized cell lines. These cell lines 
include human umbilical cord blood erythroid progenitor cells (Sosa et al, 1992) and a human 
erythroid leukaemia cell line (Takahashi et al, 1993). The availability of such cell cultures 
for B19 propagation could in future be used for the further investigation of viral replication 
and pathogenesis (Sosa et al, 1992; Takahashi et al, 1993).
-1.8.2 Viral detectionf
A high titre viraemia with levels of 10u particles per millilitre has been demonstrated at the 
onset of the non-specific prodromal symptoms (Anderson, 1991); this makes serum samples 
the specimens of choice for viral detection. A wide variety of assays has been used to 
demonstrate the presence of B19 in sera and these included electron microscopy, immune-
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electron microscopy, radioimmunoassays and enzyme immunoassays (Anderson, 1991). 
Counter-current immunoelectrophoresis (CIE) was also frequently used to demonstrate the 
presence of B19 and also had the advantage of offering a very rapid result (Sargeant et al, 
1981; Anderson, 1991).
1.8.2 Serology
Difficulties in the propagation of B19 in suitable cell lines for the production of B19 antigen 
had been the major obstacle in the development of B19 serological assays and serum or 
plasma of infected individuals had until recently been the source of antigen for antibody 
assays (Cohen et al, 1990; Anderson et al, 1991). Recombinant B19 protein and synthetic 
peptides are now the major source of antigen for use in serological assays. These antigens 
were used in an immunofluorescence assay for the detection of anti-B19 IgG and IgM 
antibodies (Brown et al, 1990) and enzyme linked immunosorbent assay (Patou et al, 1991; 
Soderlund et al, 1992); a baculovirus expression system has also been used for the 
development of antibody capture haemadherence tests for parvovirus B 19-specific IgM and 
IgG (Hilfenhaus et al, 1993).
1.8.3 DNA hybridization
B19 DNA has been demonstrated in serum samples and tissue specimens by means of DNA- 
DNA hybridization techniques (Anderson, 1991). Dot-blot hybridization, using radio-labelled 
probes (Anderson et al, 1985(c); Clewley, 1985) and colorimetric and chemiluminescent 
reactions (Azzi et al, 1990; Zerbini et al, 1993), were shown to be more sensitive than direct 
viral detection in serum (Anderson et al, 1985(c)).
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In situ hybridization for the detection of B19 DNA in formalin-fixed, paraffin-embedd 
tissues of non-immune hydrops foetalis was well described. This technique did not on 
provide a diagnosis but also demonstrated the cellular distribution of B19 in positive cas 
(Morey et al, 1992).
1.8.4 DNA amplification
DNA amplification in the form of the polymerase chain reaction, (PCR) has largely replao 
DNA hybridization in demonstrating B19 in clinical specimens due to its greater sensitivi 
(Koch et al, 1990; Erdman et al, 1991; Schwarz et al, 1992). The nested PCR, whi 
incorporated a second round of DNA amplification, has further increased the sensitivity 
this assay (Carrfere et al, 1993). This technique could be especially of value 
immunocompromised patients where a low level of circulating B19 DNA is the only eviden 
of B19 infection (Musiani et al, 1993).
The major obstacle to successful DNA amplification is DNA contamination of equipme 
and/or reagents used during these assays and special precautions have been advocated to lin 
contamination to a minimum (Kwok et al, 1989). Recently, a new DNA amplificatii 
technique was described for hepatitis B DNA amplification. This assay relied on a sing 
round of amplification consisting of 99 cycles and has demonstrated the same sensitivity 
a nested PCR assay for hepatitis B amplification (Vandenvelde et al, 1993).
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2 OBJECTIVES
THE OBJECTIVES OF THE STUDY WERE AS FOLLOWS:
2.1 EVALUATION OF DNA AMPLIFICATION TECHNIQUES IN THE DETECTION OF 
B19 DNA IN SERUM SAMPLES.
2.2 USE OF SEROLOGY AND DNA AMPLIFICATION TECHNIQUES TO EVALUATE 
THE ROLE OF B19 IN INDIVIDUALS COINFECTED WITH HIV AND TB WHO 
HAD CHRONIC ANAEMIA.
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PATIENT SELECTION3
3.1 Data extraction
Data extraction was performed on the existing databank of 307 patients included in a MRC 
study using the following parameters.
a) Anaemia on admission and lasting for 3 months (Hct <45 in males; Hct <40 in 
females)
b) HIV status
c) Age
d) Patients were identified by their hospital number
Data extraction results suggested that coinfected HIV/TB patients were more likely to 
develop chronic anaemia than patients infected with TB only.
3.2 Subjects
A total of 29 patients was identified for further evaluation of B19’s role in persistent anaemia 
in coinfected HIV/TB patients.
The 29 patients were divided into 2 matching groups (Tables la  and lb):
a) group 1 consisted of 15 coinfected HIV/TB patients;
b) group 2 consisted of 14 TB only infected patients.
Each of these groups were divided into two subgroups:
a) a group with chronic anaemia and
b) a group in which anaemia was not demonstrated over a three month period.
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Table la : Group 1: Characteristics of HIV/TB patients
Patients with chronic anaemia Patients without anaemia
Males Females Males Females
Ages 2 3 - 5 4
(34,5)
2 0 -5 3
(32,6)
2 4 - 4 8
(36)
20 - 36 
(28)
Hct on 
admission: 
range (mean)
20,1 -42,6 
(33,6)
25,0- 39,1 
(31,5)
46,8 - 52,9 
(49,9)
45,1 -47,6 
(46,4)
HCT after 3 
months: 
range (mean)
37,1 - 43,9 
(41,3)
31,9-39,8
(37,0)
55,8 - 56,2 
(56)
48,3-51,6
(50,0)
Number 6 5 2 2
Total number 
of patients 15
Table lb : Group 2: Characteristics of TB only patients
Patients with chronic anaemia Patients without anaemia
Males Females Males Females
Ages 25 - 51 
(33,7)
2 3 - 5 0
(31,8)
25 - 47 
(36,8)
2 6 -4 0
(33)
Hct on 
admission: 
range (mean)
30,9 - 44,5 
(37,2)
29,1 - 36,2 
(33,4)
45,1 - 55,2 
(49,1)
47,2 - 51,0 
(49,1)
HCT after 3 
months: 
range (mean)
39,1 - 44,5 
(42,3)
32,8 - 39,8 
(37,6)
51,6-61,8
(51,7)
47,2 - 59,4 
(53,3)
Number 5 4 3 2
Total number 
of patients 14
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4 MATERIALS AND METHODS
4.1 Serological Methods
4.1.1 Detection of anti-B19 IgG and IgM antibodies
Sera from all 29 patients were evaluated for the presence of antibodies to B19.
4.1.1.1 Detection of anti-B19 IgG antibodies
A commercially available enzyme-linked immunosorbent assay (ELISA) for the detection of 
IgG antibodies (Genoclin, GmBH Laboratories, Hamburg) against B19 was used.
4.1.1.1.1 Principle of the assay
Recombinant B19 capsid antigen is coated onto a solid phase (microtiter wells). The 
patient’s serum sample is added to the microtiter wells and if IgG antibodies against B19 are 
present, they will bind to the B19 antigen, forming antigen-antibody complexes.
These complexes are demonstrated by incubation with an anti-human IgG horseradish 
peroxidase (HRP) conjugate followed by exposure to an 0-phenylendiamine-2HCl (OPD) 
substrate. The intensity of the colour reaction is measured by a spectrophotometer with a 
filter set at 492 nm.
4.1.1.1.2 Interpretation of results 
Cut-off value
Cut-off =  Absorbance of +  absorbance of positive
negative control control
19
2
Specimens with optical density (O.D.) values >  cut-off value +10% were considered as 
positive for anti-B19 IgG antibodies.
Specimens with O.D. values <  cut-off value were considered negative for anti-B19 IgG 
antibodies.
Specimens with an O.D. value within the range of cut-off +10% were considered equivocal 
and repeated.
4.1.1.2 Detection of anti-B19 IgM antibodies
A commercially available ELISA assay for the detection of IgM antibodies (Genoclin, GmBH 
Laboratories, Hamburg) against B19 was used.
4.1.1.2.1 Pretreatment step
All specimens for anti-B19 IgM antibody detection were initially subjected to a pretreatment 
step. Patient’s serum was diluted with a specimen diluent (Biowhitaker, Maryland, U.S.A.) 
that contained and absorbent to remove IgG. The absorbent prevented IgG/rheumatoid factor 
complexes from forming and prevented interfering competition from IgG during the test 
procedure.
4.1.1.2.2 Principle of the assay
Recombinant B19 capsid antigen is coated onto a solid phase (microtiter wells). The 
patient’s sample is added to the microtiter wells and if IgM antibodies are present, they will 
bind to the B19 antigen, forming antigen-antibody complexes.
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These complexes are demonstrated by incubation with an anti-human IgM HRP conjugate 
followed by exposure to an OPD substrate. The intensity of the colour reaction is measured 
by a spectrophotometer with a filter set at 492 nm.
4.1.1.2.3 Interpretation of results 
Cut-off value
Cut-off =  Absorbance of +  absorbance of positive
negative control control
2
Specimens with O.D. values > cut-off +  10% were considered positive for anti-B19 IgM 
antibodies.
Specimens with O.D. values < cut-off +  10% were considered negative for anti-B19 IgM 
antibodies.
Specimens with O.D. values in the range cut-off +  10% were considered equivocal and 
repeated.
4.2 Polymerase chain reaction (PCR)
4.2.1 Nucleic acid extraction
DNA extraction was done by using a rapid and simple method described by Patou et al, 
1991.
4.2.1.1 Method
50fil of each specimen was added to a lOOfil solution containing 10 mmol Tris HC1 (pH 8.3), 
0,45% Nonidet-P40 (BDH chemicals, England), 0,1 mg/ml gelatin, 50 mmol potassium
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chloride and 0,006 mg proteinase K (Boehringer Mannheim GmbH, W Germany) 
Proteinase-K was separately aliquotted and added to the serum just before extraction was 
started.
This mixture was incubated at 65°C for 60 min, followed by incubation at 95°C for 10 min 
to inactivate the proteinase-K. The formed precipitate was further pelleted by centrifuging 
at 14000 rpm for 15 minutes. The supernatant was aspirated into a separate tube and 5/ri of 
this was used in the PCR assay.
4.2.2 Primer selection
Primer selection was based on results obtained by Koch et al (1990) and was restricted to 
identifying complementary sequences in the VP1 region of the parvovirus genome. 
Numbering of nucleotides is according to Shade et al (1986) (Fig. 5).
Three oligonucleotide primers, (B1 B2 and B3) were identified for use in the nested and 
rapid 99 cycle PCR assays (Fig. 5). The primers were used in the following combinations:
a) Primers B1 and B2 were used for first round amplification of the nested PCR assay 
and were also used for the rapid 99 cycle assay. The target sequence of this primer 
combination was 275 base pair (b.p.) in length.
b) Primers B3 and B2 were subsequently used for second round amplification during the 
nested PCR assay. The target region amplified by these primers was 202 base pairs.
The three primers used in the PCR assays were as follows:
1. Sense primer PVB1 (29mer):
5 CGTACAACTACCCGGTACTAACTATGTTG 3' (position 2809-^2837)
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2. Antisense primer PVB2 (30mer):
5 GCAAACITCCTTGAAAATGGGCCACAGGGG3' (in position 3054-3083)
3. Sense primer PVB3 (29mer):
5 G AC AGTGCTGCAAGG ATTCATG ACTTTAGG3' (position 2882^2910) 
These primers were designed in the NIV laboratory (S. Barr - unpublished research).
Fig. 5 Location of primers used in nested PCR and rapid 99 cycle PCR assays.
4.2.3 PCR buffer and reaction mixture
Extracted serum (5fil) or product from first round amplification (5fil) was added to a 45/xl 
reaction volume containing 50 mmol potassium chloride, 10 mmol Tris HC1 (pH 8,3), 1,5
23
mmol magnesium chloride, 0,01% gelatin, 0,1% Triton X-100, 1,5 units Taq DNA 
polymerase (Promega Corporation, Maddison, USA), 0,3 mmol of each dNTP and 0,25 
mmol of each primer. This mixture was covered with two drops of liquid paraffin, 
thoroughly mixed on a vortex mixer and then, briefly centrifuged.
4.2.4 PCR protocols
4.2.4.1 Nested PCR protocol
4.2.4.1.1 First round amplification
This reaction was performed with the primer pair B1 and B2, the PCR buffer and reaction 
mix as described. Using a programmable thermal cycler (TRIO-Thermoblock, Biometra, 
Gottingen, FRG), samples were initially pre-heated at 95°C for 3 min to facilitate complete 
denaturation of any double stranded DNA which may have been present. After this initial 
denaturation step, samples were incubated at 72°C for 3 minutes (primer annealing and 
extension) and then reheated to 94°C for 1 min (denaturation of DNA). During first round 
amplification, 35 such cycles were used, following which specimens were kept at 4°C until 
used in the second round amplification step of the nested PCR protocol.
4.2.4.1.2 Second round amplification
Conditions during this round of amplification were exactly as described for first round 
amplification, except primer pair B2 and B3 was used and the number of cycles was limited 
to 25. After the 25 cycles, specimens were kept at 4°C until run on an agarose gel.
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Specimens were prepared for amplification using the same primer pair (B1 and B2), PCR 
buffer and reaction mix as previously described for first round amplification. The 99 cycle 
amplification reaction was performed using a programmable thermal cycler equipped with 
a facility which offers tube temperature monitoring (Hybaid Ltd, U K). B19 DNA was 
amplified using 99 cycles of the following sequence: denaturation of DNA at 95°C for 1 
second, then cooling to 50°C for 1 second to allow primer annealing and then heated to 72°C 
for 1 second for primer extension. Once the 99 cycles were completed, samples were further 
incubated at 72°C for 10 minutes to allow further primer extension, this was then followed 
by storing the samples at 4°C until they were run on an agarose gel.
4.2.5 Sensitivity determination
4.2.5.1 Serum dilutions
Serum derived from a patient with hereditary spherocytosis suffering from an aplastic crisis 
previously shown to be positive by first round amplification was aliquotted and used in the 
evaluation of the sensitivity of the two amplification assays. B19 DNA amplification in serial 
10 fold dilutions of the abovementioned serum using the nested and rapid 99 cycle assays 
were evaluated.
4.2.5.2 Plasmid dilutions
Serial 10 fold dilutions of the plasmid PV-MT1, consisting of the entire B19 genome and at 
a concentration of 18 pg DNA/ml, were also used to determine the sensitivity of the nested 
and rapid 99 cycle PCR assays.
4.2.4.2 Rapid 99 cycle PCR assay
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4.2.6 PCR assay controls
4.2.6.1 Positive controls
Serum derived from a patient with hereditary spherocytosis suffering from an aplastic crisis 
previously shown to be positive by first round amplification was aliquotted and used as an 
extraction and as a positive control (1:100 000 dilution) during the nested PCR assays done 
on the specimens of the 29 patients.
4.2.6.2 Negative controls
Sera previously shown to be negative for B19 DNA was included in each DNA extraction 
round and included in each PCR assay.
The ratio of specimens to negative controls in each run was 2:1.
4.2.7 Agarose gel electrophoresis
Agarose gels were prepared by adding 2,5 gram agarose (High strength analytical 1 grade 
agarose; BioRad Laboratories, Hercules, California) to 100 ml 0,5 Tris-borate (TBE). The 
solution was heated using a microwave oven until the agarose was completely dissolved. 
The agarose solution was cooled to ±60°C and 5ul of stock ethidium bromide solution (10 
mg/ml) added. The solution was poured into a mould with the appropriate comb properly 
in place.
When the gel was completely set (±40 min at room temperature), the comb was removed 
and the gel placed into an electrophoresis tank and covered by electrophoresis buffer (0,5 
TBE).
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Samples of B19 DNA were mixed with the gel loading buffer and loaded into the individual 
wells in the gel. The electrophoresis tank was closed, the electrical leads attached and a 
voltage of 3V/cm was applied for 90 minutes.
After 90 minutes, the current was turned off, the gel removed from the tank and examined 
by UV light at 302nm, for the presence of B19 DNA. Photographs of the gels, using 
Polaroid film were then taken.
4.2.8 General considerations for PCR assays
In order to reduce the chances of generating false positive reactions during the nested and 
rapid 99 cycle assays due to contamination, general guidelines were followed (Kwok et al, 
1989). These guidelines were as follows:
4.2.8.1 Designated laboratories were used for designated reactions
Three laboratories were used during the preparation of the PCR assays:
a) Laboratory No 1 - DNA extraction of samples and controls took place in this 
laboratory.
b) Laboratory No 2 or the pre-PCR laboratory - in this laboratory preparation for the 
first round and 99 cycle assays were carried out in a biosafety hood.
c) Laboratory No 3 or post PCR laboratory - in this laboratory the agarose gels were 
run. A biosafety hood was also used for preparation of the second round PCR assay. 
All three laboratories were equipped with their own designated reagents and 
equipment such as pipettes and tubes. Separate laboratory coats were also assigned 
to each laboratory and special care was taken in changing coats between laboratories.
The biosafety hoods used were equipped with ultraviolet (UV) germicidal lamps, 
which were used to decontaminate surface areas before and after preparation of the 
PCR assays took place.
4.2.8.2 Autoclaving of tubes and reagents
All microcentrifuge tubes were autoclaved before use.
Reagents such as de-ionized water and other solutions not affected by autoclaving were 
routinely autoclaved before use.
4.2.8.3 Storage of reagents
All reagents, where possible, were aliquotted after preparation, properly marked, numbered 
and then stored in a separate area away from any amplified PCR products.
4.2.8.4 Disposable gloves
Each designated laboratory was equipped with its own supply of disposable gloves. 
Changing of gloves when moving from one laboratory also coincided with the changing of 
laboratory coats.
4.2.8.5 PCR reagent mix
All the PCR reagents used, were premixed in a cocktail and then aliquotted into the separate 
microcentrifuge tubes. Once this was completed, mineral oil was added, followed by the 
extracted sample DNA. After DNA was added the tube would be capped and only then 
would DNA be added to the next tube.
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4.2.8.6 General precautions
a) Positive displacement pipettes with their disposable tips and plungers were used in all 
the PCR assays.
b) Tubes containing sample DNA amplified modules were spun down before opening 
them. This was done to prevent splashing of liquid containing DNA when the tubes 
were opened.
c) When amplified bands were demonstrated in any of the negative controls, the results 
of that run were not recorded. The run was subsequently repeated starting from the 
extraction step.
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5 RESULTS
5.1 Sensitivity determination of the different PCR assays
5.1.1 Serum dilutions
The rapid 99 cycle amplification assay demonstrated the presence of B19 DNA in a 1:100 
000 serum dilution, while B19 DNA was demonstrated in a 1:1 000 000 serum dilution using 
the nested PCR protocol (Fig. 6).
5.1.2 Plasmid dilutions
B19 DNA could be demonstrated in 1:10 000 dilution of plasmid using the 99 cycle 
amplification assay. The nested amplification assay demonstrated the presence of B19 DNA 
in plasmid dilutions of 1:100 000 (Fig. 7).
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1 2 3 4 5 6 7  8 9  10 11
Fig. 6 Gel electrophoresis of amplified products of serum dilutions.
Lane 1 - 1:10 000 000 dilution 
Lane 2 - 1:1 000 000 dilution 
Lanes 3, 5, 8 and 10 - left open 
Lanes 4 and 9 - negative controls 
Lane 6 - 1:100 000 dilution 
Lane 7 -  1:10 000 dilution 
Lane 11 - 1:1 000 dilution
Please note: The molecular weight marker and dilutions 1:10 and 1:100 are not shown, 
but were included in the gel.
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1 2  3 4 5 6 7  8 9  10 11
275 bp 
product
202 bp 
product
1 2  3 4 5 6 7  8 9  10 11
Fig. 7 Gel electrophoresis of amplified products of plasmid dilutions.
Top gel - 99 cycle amplification 
Bottom gel - nested amplification 
Lane 1 - 1:1 000 000 dilution 
Lane 2 - 1:100 000 dilution 
Lanes 3, 5, 8 and 10 - left open 
Lanes 4 and 9 - negative controls 
Lane 6 - 1:10 000 dilution 
Lane 7 - 1:1 000 dilution 
Lane 11 -1:100 dilution
Please note: The molecular weight marker and dilutions 1:10 and 1:10 000 000 are not 
shown, but were included in the gel.
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5.2 Serological results
5.2.1 Detection of anti-B19 IgG antibodies
Anti-B19 IgG antibodies were demonstrated in 18 (62,1%) of the 29 patients (Table 2). 
Eleven of the 18 patients demonstrating anti-B19 IgG antibodies were dually infected with 
HIV and TB; 9 of these patients also had a chronic anaemia.
Seven patients infected only with TB were positive for anti-B19 IgG antibodies. Four of 
these patients suffered from chronic anaemia, while 3 patients did not demonstrate anaemia 
over the observed period.
Equivocal IgG antibody results were not demonstrated in any of the specimens.
Table 2: Anti-B19 IgG antibody results
IgG
Positive Negative
HIV/TB 
coinfected 
(n = 15)
Anaemic 9 2
Not Anaemic 2 2
Pulmonary TB 
only
(n = 14)
Anaemic 4 5
Not Anaemic 3 2
Total 18 11
5.2.2 Detection of anti-B19 IgM antibodies
Positive anti-B19 IgM antibody results were repeatedly demonstrated in specimens from 2 
(6,6%) of the 29 patients; both were dually infected with HIV and TB and had chronic 
anaemia (Table 3).
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Equivocal IgM antibody results were demonstrated in 12 (41,4%) of the 29 patients. Seven 
of the 12 patients were coinfected with HIV and TB and had chronic anaemia. The 
remaining 5 patients were infected only with TB; two of these patients had chronic anaemia 
and in 3 patients, anaemia could not be demonstrated over the 3 month period. All patients 
with equivocal or positive IgM antibody results were positive for anti-B19 IgG antibodies.
Table 3: Anti-B19 IgM antibody results
IeM
Positive Equivocal Negative
HIV/TB 
coinfected 
(n =  15)
Anaemic 2 7 2
Not Anaemic 0 0 4
Pulmonary TB 
only
(n = 14)
Anaemic 0 2 7
Not Anaemic 0 3 2
Total 2 12 15
5.3 Polymerase chain reaction results
5.3.1 First round amplification
All specimens were evaluated twice using the nested PCR assay and were thus also twice 
subjected to first round amplification. The validity of each run of 1st round amplification 
was confirmed by:
a) the demonstration of a 275 base pair (b.p.) amplified band in the positive control.
b) The absence of any demonstrable bands in the negative controls.
First round amplification was not demonstrated in any of the specimens evaluated (Fig. 8).
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1 2 3 4 5 6 7 8
275 bp 
product
700 b p -----►
600 b p ---- ►
500 b p __
475 b p ---- ►
400 b p -----►
300 b p ---- ►
------►
200 b p ---- ►
100 b p ---- ►
50 b p ---- ►
Fig. 8 Gel electrophoresis of 1st round amplification products: 
Lane 1 - molecular weight marker 
Lane 2 - positive control 
Lanes 3 and 6 - negative controls 
Lane 4 - patient No. 1182/91 
Lane 5 - patient No. 453/92 
Lane 7 - patient No. 103/92 
Lane 8 - patient No. 1238/91
5.3.2 Second round amplification of the nested PCR protocol
Validity of each 2nd round amplification run was confirmed as follows:
a) the demonstration of a 202 b.p. band in the positive control.
b) no bands were demonstrable in any of the negative controls.
Specimens from three patients were found to be positive for B19 DNA by the nested PCR 
assay. Two patients (1182/91 and 453/92) were coinfected with HIV and TB and had 
chronic anaemia (Fig. 9).
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The third patient, 103/92, was infected only with TB and did not suffer from anaemia. 
(Table 4).
All results were reproducible with repeated evaluation of specimens and no discrepant results 
were demonstrated.
1 2  3 4 5 6 7 8
202 bp 
product
Fig. 9 Gel electrophoresis of 2nd round amplification products 
Lane 1 - molecular weight marker 
Lane 7 - positive control 
Lanes 3 and 6 - negative controls 
Lane 2 - patient No. 1182/91 
Lane 4 - patient No. 453/92 
Lane 5 - patient No. 103/92 
Lane 8 - patient No. 1238/91
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Table 4 Summary of DNA amplification results
1st Round 
Amplification
2nd Round 
Amplification
Positive Negative Positive Negative
HIV/TB 
(i». -  15) 
coinfected
Anaemic 0 11 2 9
Not
Anaemic
0 4 0 4
Pulmonary TB 
(ii = 14) only
Anaemic 0 9 0 9
Not
Anaemic
0 5 1 4
Total 0 29 3 26
37
6 SUMMARY OF LABORATORY DATA OF THREE PATIENTS WITH DEMONSTRABLE
CIRCULATING B19 DNA
6.1 Introduction
Circulating B19 DNA was demonstrated in serum specimens of three patients using the 
nested PCR assay. A brief summary of laboratory data available on these patients will be 
presented. This will be followed by a short discussion on the possible significance of 
circulating B19 DNA in each of the patients.
6.2 Discussion
6.2.1 Patient N o.l; 1182/91, 54 years old, male
On admission, this patient coinfected with HIV and TB demonstrated anaemia (HCT =41,4) 
has evidence of recent exposure or persistent infection with B19 as demonstrated by a 
positive anti-B19 IgM ELISA result. The presence of low level circulating B19 DNA was 
indicated by a positive nested PCR assay.
After 3 months of routine TB treatment, the anaemia had slightly improved but was still 
present (HCT =  43,9); the anti-B19 IgM ELISA was still positive, but no circulating B19 
DNA could be demonstrated.
The CD4 count, as an indication of the level of immunosuppression, in this patient was 510 
cells/ml on admission and dropped to 330 cells/ml after three months.
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The following possible explanations could be offered for these findings:
a) The patient was infected with B19 shortly before admission or had been suffering 
from persistent B19 infection with the subsequent anaemia on admission partially due 
to B19. Following admission, the patient cleared the B19 infection which lead to the 
disappearance of B19 DNA; the detection of anti-B19 IgM 3 months after infection 
was compatible with recovery from acute infection (Erdman et al, 1991). The 
chronic anaemia was therefore probably due to other factors including HIV infection 
(Doweiko, 1993). In this instance, B19 infection would have been a coincidental 
finding and not a co-factor in persistent anaemia in this HIV/TB coinfected patient.
b) Chronic anaemia in this patient was partially due to persistent B19 infection as 
demonstrated by a low level of B19 DNA detected on admission. This low level of 
viraemia was also responsible for persistent antibody stimulation leading to a 
detectable IgM level on admission and 3 months later. B19 DNA was not 
demonstrated in the second specimen due to the following reasons:
i) it was present at very low levels in the serum and therefore not always 
demonstrable when using ethidium bromide stained agarose UV fluorescence but 
could possibly have been demonstrated using internal probing (Carribie et al, 1993);
ii) it was shed intermittently into the circulation depending on the humoral immune 
status of the patient (Kurtzman et al, 1988). In this event chronic B19 infection 
would be one of the co-factors in causing persistent anaemia in this HIV/TB 
coinfected patient.
Of these, it is probably more likely that B19 infection was at least a co-factor in 
causing persistent anaemia in this patient as the level of immunosuppression in this 
patient, as reflected by the CD4 count, did not improve over the three month period.
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As a result, it is unlikely that B19 would have been eliminated over this period and 
was most probably not detected in the second specimen due to the abovementioned 
explanations.
6.2.2 Patient No. 2; 453/92 41 years, female
This HIV/TB coinfected patient demonstrated anaemia on admission (HCT =  39,1) and had 
evidence of previous exposure to B19 (anti-B19 IgG ELISA positive). There was no 
evidence of circulating B19 DNA (nested PCR assay negative) or recent exposure to B19 
(anti-B19 IgM ELISA negative).
Three months after admission, the patient was still anaemic as demonstrated by HCT = 39,5 
and circulating B19 DNA was demonstrated by the nested PCR assay. The B19 IgM ELISA 
was equivocal, suggesting possible a humoral immune response to circulating B19.
These findings could be explained in the following manner:
A persistent B19 infection existed on admission but was not detected initially due to very low 
levels of circulating B19 or the intermittent shedding of B19 DNA (Kurtzman et al, 1988). 
Three months later, B19 DNA was still present and had also stimulated an IgM response 
which manifested as an equivocal IgM ELISA test result. In this situation B19 infection 
could be a co-factor responsible for chronic anaemia in this HIV/TB coinfected patient.
6.2.3 Patient No. 3; 103/92, 26 years old, female
This TB only infected patient shows a dramatic improvement in haematological parameters 
3 months after admission, a picture commonly seen in hospitalised TB patients receiving 
routine TB treatment (Dr B Miller - personal communication). On admission, this patient 
also has evidence suggestive of recent exposure to B19 infection as demonstrated by an
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equivocal anti-B19 IgM ELISA result, detection of circulating B19 DNA and a detectable 
IgG response. The evidence here therefore, suggests that this patient was infected with B19 
shortly before admission, and part of the haematological picture seen on admission was due 
to the effect of an acute B19 infection (Potter et al, 1987). The patient’s immune response 
was subsequently responsible for clearing the infection, and 3 months later no haematological 
or virological evidence suggestive of persistent B19 infection was present.
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Table 5: Summary of laboratory data on each patient
Patient No 1; 54 yrs, male Patient No 2; 41 yrs, female Patient No 3; 26 yrs, feamle
Admission:
18/3
Follow up: 
8/6
Admission:
22/1
Follow up: 
22/4
Admission:
22/1
Follow up: 
22/4
HCT 41,4 43,9 39,1 39,5 47.2 59,4
RBCC 4,07 4,18 3,42 3,64 5,20 5,02
UCC 13,0 6.3 10,2 7.1 8,8 8,9
Total
Lymphocytes 5070 2210 2040 1920 1230 1510
Monocytes 520 440 510 500 620 450
Polymorphs 7410 3650 7650 4620 6950 6940
CD4 cells 510 330 820 860 470 510
T8 cells 4770 1770 940 920 540 710
B19 IgM ELISA + + . Equivocal Equivocal _
B19 IgG ELISA + + + + + +
B19 Nested PCR + - . + + -
HIV Status + + + + _ .
TB treatment 
(a)Isoniazid + + + + + +
(b)Rifampicin + + + + + +
(c)Pirazinamide + + + + + +
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7 DISCUSSION
Recent reports have demonstrated that HIV infected individuals and AIDS patients were 
prone to develop chronic anaemia following B19 infection (Frickhofen et al, 1990. Nigro et 
al, 1992). The ever increasing numbers of HIV infected individuals and AIDS patients in 
Africa may thus be at a potential risk of developing chronic anaemia due to persistent B19 
infection. In this preliminary study the primary objective was to evaluate the role of B19 in 
a subgroup of the HIV infected individuals, namely coinfected HIV/TB patients with chronic 
anaemia using serological methods and DNA amplification assays.
7.1 Sero-epidemiology
Most B19 seroprevalence studies have until recently not addressed B19 seroprevalence in 
HIV infected individuals. Only lately has interest been generated in the sero-epidemiology 
of B19 in HIV infected individuals with most of these reports originating in the developed 
world (Frickhofen et al, 1990; Nigro et al, 1992; Arakelov et al, 1993). These reports 
suggested that B19 seroprevalence was increased in HIV infected individuals. No reports 
have been published on the seroepidemiology of B19 in immunocompromised patients in 
South Africa. In this preliminary study, the following observations were noted when the 
presence of anti-B19 antibodies were used as evidence of past exposure to B19.
Firstly, a greater proportion of patients in this study group (62%) demonstrated serological 
evidence of past exposure to B19 when compared to the adult seroprevalence rates recently 
reported in South Africa (25%) (Schoub et al, 1993).
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Secondly, in the HIV-TB coinfected group more patients with persistent anaemia 
demonstrated evidence of past exposure to B19 than those without anaemia, 82% vs. 18% 
respectively, although the numbers are too small to make any statistical correlation. This 
tendency was not demonstrated in the group of pulmonary TB patients not infected with HIV. 
These two observations would suggest the following:
a) Factors or conditions facilitating the transmission of TB may also facilitate the 
transmission of B19. Poor socio-economic conditions and over-crowding are 
commonly associated with the transmission of TB and may thus also play a role in 
B19 transmission as respiratory spread is thought to be the major route of 
transmission for this virus. Malnutrition with an accompanying immunosuppression 
is also associated with the acquisition of TB and may theoretically in a B19 infected 
individual result in viral persistence, a prolonged carriage and excretion of B19 with 
the resultant increase of chance of transmission to non-immune individuals.
b) Previous evidence of B19 infection may be associated with chronic anaemia in HIV- 
TB coinfected individuals; this could be the result of B19 persistence (Kurtzman et 
al, 1987, Frickhofen et al, 1990) in the immunocompromised patients.
These seroepidemiological results are however from a small, highly selected group of 
individuals and can therefore not be interpreted as being conclusive of any definite 
serological trend.
7.2 IgM assays
The performance of IgM assays could be compromised by a variety of factors. These 
include the following:
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a) Repeated freezing and thawing of specimens compromise the integrity of the IgM 
macromolecule often leading to false negative results.
b) The interference of rheumatoid factor (RF) with the IgM assay. This problem is 
addressed by the evaluation of all IgM positive specimens for the presence of RF.
c) IgG antibodies could occupy antibody sites in the IgM assay interferring with the 
result. Currently this can be circumvented by the use of a specific IgG antibody 
absorbent as pretreatment before performing IgM assays. The development of 
specific IgM capture antibody assays such as the ELISA (Yaegashi et al, 1989; Patou 
et al, 1991; Erdman et al, 1991) has now eliminated this problem.
d) Non-specific polyclonal B-cell activation by agents such as EBV, HHV6 and HIV 
resulting in false positive IgM assay results.
Conditions for the performance of anti-B19 IgM tests were not ideal due to the retrospective 
nature of the study. These specimens were initially used for other serological assays and 
freezed and thawed at least twice before being submitted for anti-B19 IgM antibody testing, 
and results obtained with this assay should be interpreted with this in mind. Positive anti- 
B19 IgM results over a 3 month period were demonstrated in only 2 patients, both were 
infected with HIV and TB and had a chronic anaemia. This would suggest that these patients 
experienced either a primary infection (Erdman et al, 1991) or re-infection (Schoub et al, 
1993) before admission with the subsequent IgM response lasting three months. 
Alternatively, they were exposed before admission and re-exposed between admission and 
follow-up to either a reinfection or reactivation with a low-level circulating B19 (Kurtzman 
et al, 1988) which elicited a detectable IgM response. Intermittent low-level circulating B19 
could not only stimulate a demonstrable anti-B19 IgM response but would also be compatible
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with B19 persistence (Frickhofen et al, 1990) and chronic anaemia observed in these patients 
(Kurtzman et al, 1988; Coulombel et al, 1989; Nigro et al, 1992). Insufficient serum was 
available for the performance of the urea denaturation test which could have distinguished 
between primary or secondary infection (Schoub et al, 1993).
Interpretation of the equivocal IgM results is impossible in view of the suboptimal conditions 
which existed for IgM testing. It should also be remembered that the majority of equivocal 
IgM results occurred in patients infected with HIV which could in itself be responsible for 
polyclonal B-cell activation resulting in such results. Although small in numbers, the results 
of the anti-B19 IgM assays nevertheless tend to suggest that a greater proportion of patients 
coinfected with HIV-TB patients with anaemia were recently exposed to B19 compared to 
those without anaemia. This would also be compatible with a hypothesis that coinfected 
anaemia patients were more likely to harbour persistent B19 infection.
7.3 Amplification
DNA amplification techniques, especially the nested PCR assay, have been shown to be 
highly sensitive in demonstrating low levels of circulating B19 DNA (Koch et al, 1990; 
Carribre et al, 1993; Musiani et al, 1993). The generation of false positive reactions as a 
result of contamination during the assays has always been a major obstacle in the 
reproducibility of results. During this study strict measures (Kwok et al, 1989) were taken 
to prevent contamination and this resulted in the reproducibility of all results.
The presence of circulating B19 DNA could not be demonstrated after first round 
amplification and was only shown after 2nd round amplification of the nested PCR assay.
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The nested PCR assay demonstrated the presence of low level circulating B19 DNA in 3 
patients. Two of these patients, both HIV-TB coinfected with chronic anaemia, had 
haematological pictures compatible with persistent B19 infection, the presence of B19 DNA 
could not be demonstrated repeatedly over a 3 month period in these patients; this would be 
consistent with a persistent B19 infection.
The third patient had no clinical, haematological or virological features suggestive of a 
persistent B19 infection after 3 months of routine TB treatment; suggesting that the results 
obtained on admission were most probably due to a primary infection of B19 occurring 
shortly before admission which resolved without the development of sequelae associated with 
persistent B19 infection.
7.4 Sensitivity evaluation
The other objective of the study was to compare the nested and rapid 99 cycle PCR assays 
in the detection of B19 DNA in serum samples, as the sensitivity of the 99 cycle assay was 
shown to be comparable with that of the nested PCR when HBV DNA was detected 
(Vandenvelde et al, 1993). Should the 99 cycle assay be shown to have the same sensitivity 
as the nested PCR assay in detecting the presence of B19 DNA it would have the advantage 
of reducing the risk of contamination as only 1 round of amplification is undertaken with this 
assay.
The sensitivity of the nested PCR assay and the rapid 99 cycle assay was compared using 
serial 10 fold dilutions of a known positive control serum and a positive plasmid control. 
Serial 10 fold dilutions of the positive control specimen and the plasmid positive control both 
demonstrated that the nested assay could detect a 10 fold greater dilution of B19 DNA than
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the rapid assay. Both these evaluations thus demonstrated that the nested assay was more 
sensitive than the rapid 99 cycle assay in demonstrating circulating B19 DNA. It should be 
pointed out that the conditions for the 99 cycle protocol were not optimized before use in this 
study and the results obtained here should not be regarded as conclusive until further 
evaluations have been done to establish optimal performance conditions for this assay. 
Future consideration should be given to using either radiolabelled, digoxigenin-labelled (DIG) 
or biotin labelled probes in demonstrating amplified products after PCR assay as this may 
enhance the sensitivity of these assays, especially in patients with a chronic B19 infection as 
these patients may have very low levels of circulating B19 DNA (Carrifcre et al, 1993).
7.5 Role of B19 in HIV/TB patients with anaemia
In conclusion, the virological evaluation of these 29 highly selected patients demonstrated 
several noteworthy trends. Firstly, proportionally more patients infected with TB had 
evidence of previous exposure to B19 than patients attending an ante-natal clinic (Schoub et 
al, 1993); a greater proportion of patients coinfected with HIV/TB with anaemia 
demonstrated evidence of post exposure to B19 than those without anaemia. Secondly, a 
greater percentage of coinfected HIV and TB patients with persistent anaemia demonstrated 
evidence of recent exposure to B19 when compared to the coinfected group without anaemia. 
Thirdly, circulating B19 DNA was demonstrated in the serum of 2 coinfected individuals 
with haematological pictures compatible with persistent B19 infection; the presence of B19 
DNA could not be demonstrated in coinfected individuals without anaemia. Together these 
serological and DNA amplification assays results would suggest a possible role - either causal 
or cofactorial - for persistent B19 infection in the establishment of chronic anaemia in HIV
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and TB coinfected patients. A larger prospective study is needed to provide more conclusive
answers.
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